Background The beneficial effect of low-dose aspirin in the prevention of coronary vasospasm is well documented. In this study, we investigated the contractile effect of human washed platelets on the human isolated coronary artery. We concentrated on the effect of low-dose aspirin (40 mg/d) taken by the platelet donor and on the efficacy of thromboxane A2 (TXA2) and 5-hydroxytryptamine (5-HT) receptor antagonists.
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Methods and Results Human coronary artery segments were suspended in an organ bath set-up for isometric tension measurement. Platelets (109 to 3 x 10/1L) elicited concentration-dependent contractile responses of the coronary artery segments, reaching 28.4±7.1% of contractions induced by 100 mmol/L K'. The contractile response tended to be decreased in vessel segments with histological signs of early atherosclerosis. Contraction was significantly attenuated after pretreatment of the vessel segments with ketanserin (5-HT2 receptor antagonist, 1 ,umol/L) or SQ30741 (TXA2 receptor antagonist, 0.01 ,umol/L), reaching 8.8±2.3% and 3.2±2.2% of contraction to 100 mmol/L K', respectively. Platelets obtained from A spirin has been shown extensively to be effective in the prevention of a number of cardiovascular diseases. A daily dose of 325 mg reduced the risk of myocardial infarction by 44%.1 Even a much lower dose, 20 to 40 mg, caused complete inhibition of the synthesis of thromboxane A2 (TXA2),2 which, together with 5-hydroxytryptamine (5-HT, serotonin), forms the major vasoconstrictor products involved in platelet-induced vasocontraction.3, This same dose of aspirin (20 to 40 mg daily) hardly affected the endothelial production of prostacyclin (PGI2), which has antiaggregatory and vasorelaxant effects.56 Guided by the latter observations, clinical investigators have focused their attention on low doses of aspirin. Thus, 75 mg aspirin daily resulted in a significant (60%) reduction of aspirin the risk of myocardial infarction and subsequent death7 in silent as well as in symptomatic ischemia. 8 An even lower dose of aspirin, 30 mg, was found to be equally effective in the prevention of vascular events and had fewer adverse effects than a 283-mg dose in patients with a transient ischemic attack or minor stroke.9 Damage of the endothelial lining of the vascular wall is thought to incite platelet adhesion to the exposed subendothelial collagen, with the subsequent release of platelet products.10'1' Experimentally induced atherosclerosis in monkeys was found to alter the response to important platelet products like 5 -HT, ADP, and TXA2 in a direction that would favor vasoconstriction when these products are released from aggregating platelets. 12 Indeed, elevated levels of both 5 -HT13 and thromboxane B2 (TXB2), the stable metabolite of TXA2, 14, 15 have been observed in patients with coronary artery lesions and angina.
In the present experiments, we investigated the effect of low-dose aspirin, taken by the platelet donors, on platelet-induced contractions of the human isolated coronary artery. We concentrated on the relative importance of cyclooxygenase products and 5 -HT, before and after aspirin treatment. We attempted to relate the readily activated after they were added to the organ bath, resulting in platelet product release and consequential functional responses, we did not further regulate or induce the state of platelet activation. Care was taken to minimize the time during which the platelets had to be kept before they were added (<35 minutes). After the first experiment, the platelet donors were treated with aspirin (acetylsalicylic acid, Pharmachemie bv, Haarlem, The Netherlands) 40 mg/d, once daily, at regular intervals until human coronary tissue was again available for experimentation. This period varied between 7 and 13 days. Then, another 23 mL of blood was drawn from the platelet donor, and the experiment was repeated as described above.
Determination of the Concentration of Eicosanoids and 5-HT Thirty minutes after the highest concentration of platelets was added, a 1.8-mL sample was drawn from the organ bath in a polypropylene tube, and indomethacin (30 ,umol/L) was added to stop cyclooxygenase activity. The samples were centrifuged at 570g for 20 minutes. The solution above the pellet was pipetted off and stored at -80°C until assay. The following eicosanoids were determined in this organ bath sample: TXB2,. PGE2, and 6-keto-PGFla (stable metabolite of PGI2). Twenty-microliter (TXB2) and 100-,uL (PGE2 and 6-keto-PGF1J) portions of the organ bath solution were used for radioimmunoassay.16 Tritiated compounds were purchased from Amersham (UK), standards from Sigma Chemical Co (St Louis, Mo), and antisera from Advanced Magnetics Inc. The lower detection limits of the TXB2, PGE2, and 6-keto-PGFi,, assays were 1.25, 2.5, and 5 pg per tube, respectively. Radioactivity was determined by counting scintillation with a Packard 1500 Tricarb. Calculations were performed with additional software using spline functions.
5-HT was determined by high-performance liquid chromatography (HPLC) with electrochemical detection. Organ bath solution (400 ,L) was mixed with an equal amount of mobile phase, and 20-gL samples were injected onto a reversed-phase column (Bio-Sil C18 A/B, 5 ,um, 150x4.6 mm, Bio-Rad Laboratories, Brussels, Belgium). The Fig 1) .
During the period in which the platelet donors took aspirin (range, 7 to 13 days), no adverse effects were observed. The contractile response to platelets obtained after aspirin treatment was significantly decreased, reaching a maximum of only 7.6±2.7% of potassiuminduced contraction (Fig 2) . Although SQ30741 (0.01 ,umol/L) was more potent than ketanserin (1 ,ltmol/L) against untreated platelets (Fig 1) , ketanserin appeared to be more potent than SQ30741 against platelets from aspirin-treated platelet donors. As depicted in Fig 3,  SQ30741 [C] ) control situation where no antagonist was present. *Significantly different from the concentration measured for control platelets; tsame as * but also significantly different from the detection limit for this compound; the aspirin-treated control situation was compared with the nontreated situation. tSignificantly different from the untreated control situation. In samples in which the eicosanoid or 5-HT could not be detected, the concentration was assumed to equal the lower detection limit concentration. (Table) . Although the vessel segments in our study had not been exposed to aspirin, this same dose has previously been shown to preserve prostacyclin production in humans in vivo.56 6-Keto-PGF,l, could only be detected after addition of platelets to the organ bath, indicating a presumably endothelial response to platelets or platelet products and the absence of a basal prostacyclin production in vitro.32 TXB2 was detected in the organ bath even when no platelets had been added, indicating basal vascular production of TXA2, although TXA2 derived from leftover tissue-donor platelets cannot be entirely excluded. The concentration of 5-HT was left unchanged by the treatment with low-dose aspirin. Apart from HPLC measurements, this could also be reasoned from the fact that ketanserin was still significantly active as an antagonist after treatment of the platelets with aspirin (Fig 3) , whereas SQ30741 caused only minor, nonsignificant additional attenuation of the residual contractile response. This was presumably a result of a decrease of the TXA2-induced part of the platelet-induced contractile response caused by treatment with aspirin.
Correlation of Histology and Functional Parameters
Despite the fact that the coronary arteries were obtained from relatively young, apparently healthy organ donors, most vessel segments showed modest, agerelated signs of atherosclerosis: intimal hyperproliferation, internal elastic lamina fragmentation, and luminal occlusion. It must be kept in mind, however, that we avoided the use of vascular segments with distinct, macroscopically visible, atherosclerotic lesions. This analysis therefore refers only to early atherosclerotic development. The present CADS appears to be in line with Ginsburg et al,17 who found that CADS in coronary arteries ranged from 1.5 between 10 and 20 years of age up to 2.2 between 40 and 50 years of age. We observed that relaxation to substance P was inversely correlated with the development of early atherosclerosis, confirming earlier reports concluding that atherosclerosis reduces the endothelium-dependent, NO-mediated, relaxant response to substance P in the human isolated coronary artery. '8'33 In contrast to some animal models,34'35 we observed a tendency toward a decreased platelet-induced contractile response in mildly diseased vessel segments. In the present setup, both the luminal and serosal sides were exposed to the platelet products. Kaul 
